Clinical Trial

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal and Leptomeningeal Metastases
Trial Details
NCT Number NCT07304739
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Non Small Cell Lung Cancer
Enrollment 30 participants
Start Date 2025-12-22
Primary Completion 2028-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-26